Clinical Trial Update: Efficacy and Safety of Tofacitinib in Refractory Blau Syndrome [Phase 4]

View source ↗

Summary

Phase 4 clinical trial update evaluating the efficacy and safety of tofacitinib in refractory Blau syndrome. Enrollment is by invitation.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Blau Syndrome

Drugs mentioned

• Tofacitinib (Xeljanz) (tofacitinib)

Snippet

Sponsor: Peking Union Medical College Hospital | Conditions: Blau Syndrome | Phase 4 | Status: ENROLLING_BY_INVITATION